Edition:
India

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

34.30USD
18 Sep 2020
Change (% chg)

-- (--)
Prev Close
$34.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
511,706
52-wk High
$37.00
52-wk Low
$10.09

Latest Key Developments (Source: Significant Developments)

Aimmune "Cautions Stakeholders Against Drawing Conclusions" From ICER's Report On Emerging Desensitization Treatments For Peanut Allergy
Thursday, 11 Jul 2019 

July 11 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE STATEMENT ON INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER) FINAL REPORT ON AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS-"CAUTIONS STAKEHOLDERS AGAINST DRAWING CONCLUSIONS" FROM ICER'S REPORT ON EMERGING DESENSITIZATION TREATMENTS FOR PEANUT ALLERGY.  Full Article

Aimmune Therapeutics Reports Q1 Loss Per Share $0.87
Thursday, 9 May 2019 

May 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.87.Q1 EARNINGS PER SHARE ESTIMATE $-0.97 -- REFINITIV IBES DATA.  Full Article

U.S. FDA Accepts BLA Filing Of Aimmune Therapeutics' AR101 For Peanut Allergy
Monday, 18 Mar 2019 

March 18 (Reuters) - Aimmune Therapeutics Inc ::U.S. FDA ACCEPTS BLA FILING OF AIMMUNE THERAPEUTICS’ AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - FDA INFORMED CO THAT BLA WILL BE REVIEWED UNDER A TWELVE-MONTH TARGET REVIEW PERIOD, AS MEASURED FROM JANUARY 2019 START DATE.AIMMUNE THERAPEUTICS INC - REVIEW OF BLA MAY TAKE UNTIL LATE JANUARY 2020.AIMMUNE THERAPEUTICS INC - CURRENTLY ENGAGED IN DISCUSSIONS WITH FDA REGARDING REVIEW TIMELINE FOR AR101 BLA.AIMMUNE THERAPEUTICS INC - FDA EXPECTS TO CONVENE ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION FOR AR101.  Full Article

Aimmune Therapeutics Says As A Result Of U.S. Govt Shutdown, Other, FDA Will Not Commence Review Of Co's Bla For Ar101
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS - NOTIFIED BY FDA AS A RESULT OF U.S. GOVERNMENT SHUTDOWN, OTHER, FDA WILL NOT COMMENCE REVIEW OF CO'S BLA FOR AR101.AIMMUNE THERAPEUTICS INC - FDA INDICATED IT WILL INITIATE REVIEW OF BLA WHEN THE U.S. GOVERNMENT SHUTDOWN AND LAPSE IN APPROPRIATIONS HAS ENDED.  Full Article

Aimmune Therapeutics Inc - Announced Exclusive Supply Agreement For Egg Protein With Michael Foods
Thursday, 20 Dec 2018 

Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES IND FILING FOR AR201 FOR EGG ALLERGY AND EXCLUSIVE SUPPLY AGREEMENT WITH MICHAEL FOODS.AIMMUNE THERAPEUTICS INC - AR201 FOR EGG ALLERGY PHASE 2 INITIATION PLANNED FOR 2019.AIMMUNE THERAPEUTICS INC - ANNOUNCED EXCLUSIVE SUPPLY AGREEMENT FOR EGG PROTEIN WITH MICHAEL FOODS.  Full Article

Aimmune Therapeutics Announces Closing Of $98 Mln Investment By Nestlé Health Science
Thursday, 29 Nov 2018 

Nov 28 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES CLOSING OF $98 MILLION INVESTMENT BY NESTLÉ HEALTH SCIENCE.AIMMUNE THERAPEUTICS - NESTLÉ HEALTH SCIENCE PURCHASED 3.2 MILLION NEWLY ISSUED CO'S SHARES AT $30.27/SHARE.AIMMUNE THERAPEUTICS INC - SALE OF SHARES WAS MADE PURSUANT TO TERMS OF SECURITIES PURCHASE AGREEMENT ENTERED INTO ON NOVEMBER 11.  Full Article